Tenaya therapeutics presents encouraging new clinical and preclinical data from hdac6 inhibitor program tn-301 for the potential treatment of heart failure with preserved ejection fraction at the 2023 hfsa annual scientific meeting

Tn-301 demonstrates tolerability, potential for once daily dosing, target engagement and selectivity for hdac6 in phase 1 clinical trial of healthy participants
TNYA Ratings Summary
TNYA Quant Ranking